厄贝沙坦联合胰激肽原酶治疗早期糖尿病肾病疗效观察

目的 探讨厄贝沙坦联合胰激肽原酶治疗早期糖尿病肾病的临床疗效。方法 选择2013年6月至2015年3月安徽省第二人民医院内分泌科80例早期糖尿病肾病患者，随机分为对照组和治疗组各40例。对照组给予厄贝沙坦治疗，治疗组给予厄贝沙坦联合胰激肽原酶治疗。对比分析24 h尿微量白蛋白排泄率（24 h UAER）、血脂、平均动脉压（MAP）及血流动力学指标的变化。结果 治疗组24 h UAER、血脂、MAP及血流动力学指标较对照组显著下降，差异有统计学意义（P<0.05）。结论 厄贝沙坦联合胰激肽原酶治疗早期糖尿病肾病能有效改善肾功能，延缓其发展，值得临床推广使用。

Effect observation of irbesartan combined with pancreatic kininogenase in treatment of early diabetic nephropathy

Objective To evaluate the clinical efficacy of irbesartan combined with pancreatic kininogenase in the treatment of early diabetic nephropathy. Methods From Jun 2013 to Mar 2015, eighty patients with early diabetic nephropathy were selected from our department and randomly divided into the control group and the treatment group, 40 cases in each group. Patients in the control group were treated with irbesartan alone, while the treatment group was given irbesartan and pancreatic kininogenase, and results of such indexes as 24-hour urinary albumin excretion rate (UAER), blood lipids, mean arterial pressure (MAP), hemodynamic changes between them were compared and analyzed. Results Fall in the levels of 24-hour UAER, blood lipids, MAP, and hemodynamic index were more notable in the treatment group than those in the control group, and the differences between them were significant (P<0.05). Conclusion Irbesartan combined with pancreatic kininogenase in the treatment of early diabetic nephropathy could improve the renal function effectively, delay the development of diabetic kidney disease, and therefore, it is worthy of clinical application.